WFRF:(Bartoletti A)
Search: WFRF:(Bartoletti A) > Risk factors for re...
- 5 of 15
- Previous record
- Next record
- To hitlist
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 06762naa a2200673 4500 | |
| 001 | oai:DiVA.org:uu-453572 | |
| 003 | SwePub | |
| 008 | 210922s2021 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4535722 URI |
| 024 | 7 | a https://doi.org/10.1016/j.acuro.2020.08.0162 DOI |
| 040 | a (SwePub)uu | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Pisano, F.u Univ Studies Turin, Citta Salute & Sci Torino, Turin, Italy.;Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain.4 aut |
| 245 | 1 0 | a Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients |
| 264 | 1 | b ENE EDICIONES SL,c 2021 |
| 338 | a print2 rdacarrier | |
| 520 | a Introduction and objectives: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis in order to adequately stage the patient. It is well known that the presence of detrusor muscle in the specimen is a prerequisite to minimize the risk of under staging. Persistent disease after resection of bladder tumors is not uncommon and is the reason why the European Guidelines recommended a re-TUR for all T1 tumors. It was recently published that when there is muscle in the specimen, re-TUR does not influence progression or cancer specific survival. We present here the patient and tumor factors that may influence the presence of residual disease at re-TUR.Material and methods: In our retrospective cohort of 2451 primary T1G3 patients initially treated with BCG, pathology results for 934 patients (38.1%) who underwent re-TUR are available. 74% had multifocal tumors, 20% of tumors were more than 3 cm in diameter and 26% had concomitant CIS. In this subgroup of patients who underwent re-TUR, there was no residual disease in 267 patients (29%) and residual disease in 667 patients (71%): Ta in 378 (40%) and T1 in 289 (31%) patients. Age, gender, tumor status (primary/recurrent), previous intravesical therapy, tumor size, tumor multi-focality, presence of concomitant CIS, and muscle in the specimen were analyzed in order to evaluate risk factors of residual disease at re-TUR, both in univariate analyses and multivariate logistic regressions.Results: The following were not risk factors for residual disease: age, gender, tumor status and previous intravesical chemotherapy. The following were univariate risk factors for presence of residual disease: no muscle in TUR, multiple tumors, tumors >= 3 cm, and presence of concomitant CIS. Due to the correlation between tumor multi-focality and tumor size, the multivariate model retained either the number of tumors or the tumor diameter (but not both), p < 0.001. The presence of muscle in the specimen was no longer significant, while the presence of CIS only remained significant in the model with tumor size, p < 0.001.Conclusions: The most significant factors for a higher risk of residual disease at re-TUR in T1G3 patients are multifocal tumors and tumors more than 3 cm. Patients with concomitant CIS and those without muscle in the specimen also have a higher risk of residual disease. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng |
| 653 | a Non-muscle invasive bladder cancer | |
| 653 | a Re-transurethral resection of the bladder | |
| 653 | a Residual disease | |
| 653 | a Recurrence | |
| 653 | a Progression | |
| 700 | 1 | a Gontero, P.u Univ Studies Turin, Citta Salute & Sci Torino, Turin, Italy.4 aut |
| 700 | 1 | a Sylvester, R.u EORTC Headquarters, Dept Biostat, Brussels, Belgium.4 aut |
| 700 | 1 | a Joniau, S.u Univ Hosp Leuven, Dept Urol, Oncol & Reconstruct Urol, Leuven, Belgium.4 aut |
| 700 | 1 | a Serretta, Vu Univ Palermo, Dept Surg Oncol & Stomatol Sci, Palermo, Italy.4 aut |
| 700 | 1 | a Larre, S.u Univ Oxford, John Radcliffe Hosp, Dept Surg Sci, Oxford, England.4 aut |
| 700 | 1 | a Di Stasi, S.u Policlin Tor Vergata Univ Rome, Rome, Italy.4 aut |
| 700 | 1 | a van Rhijn, B.u Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Urol, Amsterdam, Netherlands.4 aut |
| 700 | 1 | a Witjes, A.u Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands.4 aut |
| 700 | 1 | a Grotenhuis, A.u Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands.4 aut |
| 700 | 1 | a Colombo, R.u Univ Vita Salute, Dipartimento Urol, Osped S Raffaele, Milan, Italy.4 aut |
| 700 | 1 | a Briganti, A.u Univ Vita Salute, Dipartimento Urol, Osped S Raffaele, Milan, Italy.4 aut |
| 700 | 1 | a Babjuk, M.u Univ Praha, Motol Hosp, Dept Urol, Prague, Czech Republic.4 aut |
| 700 | 1 | a Soukup, Vu Univ Praha, Motol Hosp, Dept Urol, Prague, Czech Republic.4 aut |
| 700 | 1 | a Malmström, Per-Unou Uppsala universitet,Urologkirurgi4 aut0 (Swepub:uu)perunoms |
| 700 | 1 | a Irani, J.u Hosp Bicetre, Dept Urol, Le Kremlin Bicetre, France.4 aut |
| 700 | 1 | a Malats, N.u Spanish Natl Canc Res Ctr CNIO, Genet & Mol Epidemiol Grp, Madrid, Spain.4 aut |
| 700 | 1 | a Baniel, J.u Rabin Med Ctr, Dept Urol, Tel Aviv, Israel.4 aut |
| 700 | 1 | a Mano, R.u Rabin Med Ctr, Dept Urol, Tel Aviv, Israel.4 aut |
| 700 | 1 | a Cai, T.u Santa Chiara Hosp, Dept Urol, Trento, Italy.4 aut |
| 700 | 1 | a Cha, E.u Mem Sloan Kettering Canc Ctr, Dept Urol, 1275 York Ave, New York, NY 10021 USA.4 aut |
| 700 | 1 | a Ardelt, P.u Univ Hosp Basel, Urol Univ Clin Basel Liestal, Basel, Switzerland.4 aut |
| 700 | 1 | a Varkarakis, J.u Univ Athens, Sismanoglio Hosp, Dept Urol, Athens, Greece.4 aut |
| 700 | 1 | a Bartoletti, R.u Univ Florence, Dept Expt & Clin Med, Florence, Italy.4 aut |
| 700 | 1 | a Dalbagni, G.u Mem Sloan Kettering Canc Ctr, Dept Urol, 1275 York Ave, New York, NY 10021 USA.4 aut |
| 700 | 1 | a Shariat, S. F.u Med Univ Vienna, Dept Urol, A-1190 Vienna, Austria.;Cochin Hosp, Dept Urol, Paris, France.4 aut |
| 700 | 1 | a Xylinas, E.u Mayo Clin, Dept Urol, Rochester, MN USA.4 aut |
| 700 | 1 | a Karnes, R. J.u Mayo Clin, Dept Urol, Rochester, MN USA.4 aut |
| 700 | 1 | a Palou, J.u Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain.4 aut |
| 710 | 2 | a Univ Studies Turin, Citta Salute & Sci Torino, Turin, Italy.;Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain.b Univ Studies Turin, Citta Salute & Sci Torino, Turin, Italy.4 org |
| 773 | 0 | t Actas Urológicas Españolasd : ENE EDICIONES SLg 45:6, s. 473-478q 45:6<473-478x 0210-4806x 1699-7980 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-453572 |
| 856 | 4 8 | u https://doi.org/10.1016/j.acuro.2020.08.016 |
Find in a library
- Actas Urológicas Españolas (Search for host publication in LIBRIS)
To the university's database
- 5 of 15
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Pisano, F.
- Gontero, P.
- Sylvester, R.
- Joniau, S.
- Serretta, V
- Larre, S.
- show more...
- Di Stasi, S.
- van Rhijn, B.
- Witjes, A.
- Grotenhuis, A.
- Colombo, R.
- Briganti, A.
- Babjuk, M.
- Soukup, V
- Malmström, Per-U ...
- Irani, J.
- Malats, N.
- Baniel, J.
- Mano, R.
- Cai, T.
- Cha, E.
- Ardelt, P.
- Varkarakis, J.
- Bartoletti, R.
- Dalbagni, G.
- Shariat, S. F.
- Xylinas, E.
- Karnes, R. J.
- Palou, J.
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Urology and Neph ...
- Articles in the publication
- Actas Urológicas ...
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
